Dataset Information

Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.

ABSTRACT:

Background

Luminal breast cancers with high proliferation (MKS^hi) and low ER-related signalling (ERS^lo) have a poor prognosis. We investigated treatment responses and molecular features of MKS^hi/ERS^lo tumours to inform potential therapies.

Methods

Gene expression data from patients who received neoadjuvant chemotherapy (NAC) without (MDACC, N = 199) or with pembrolizumab (I-SPY2, N = 40), or endocrine therapy (NET) without (POETIC, N = 172) or with palbociclib (NeoPalAna, N = 32) were analyzed to assess treatment response by MKS/ERS-subgroups. TCGA was used to assess the mutational landscape and biomarkers associated with palbociclib-resistance (Cyclin-E, RBsig, IRPR) and immunotherapy-response (TMB, TILs, T-cell inflamed) by MKS/ERS-subgroups.

Results

Compared to MKS^hi/ERS^hi tumours, MKS^hi/ERS^lo tumours had higher pathological response rates to NAC (22% vs 8%, p = 0.06) but a higher recurrence risk (4-year metastasis-free survival 70% vs 94%, p = 0.01). MKS^hi/ERS^lo tumours frequently harboured TP53 (34%) and PIK3CA (33%) mutations, and showed high expression of Cyclin-E, RBsig and IRPR, high TMB and elevated TIL and T-cell inflamed metagene expression. MKS^hi/ERS^lo tumours retained high proliferation after NET with or without palbociclib but had higher pathological complete response rates when pembrolizumab was added to NAC (42% vs 21%, p = 0.07).

Conclusions

MKS^hi/ERS^lo tumours have dismal outcomes and are enriched in chemotherapy-sensitive but ET- and palbociclib-resistant tumours. Biomarker analysis and clinical data suggest a potential role for immunotherapy in this group.

SUBMITTER: Licata L

PROVIDER: S-EPMC10703787 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.

Licata Luca L Barreca Marco M Galbardi Barbara B Dugo Matteo M Viale Giulia G Győrffy Balàzs B Karn Thomas T Pusztai Lajos L Gianni Luca L Callari Maurizio M Bianchini Giampaolo G

British journal of cancer 20231107 12

<h4>Background</h4>Luminal breast cancers with high proliferation (MKS<sup>hi</sup>) and low ER-related signalling (ERS<sup>lo</sup>) have a poor prognosis. We investigated treatment responses and molecular features of MKS<sup>hi</sup>/ERS<sup>lo</sup> tumours to inform potential therapies.<h4>Methods</h4>Gene expression data from patients who received neoadjuvant chemotherapy (NAC) without (MDACC, N = 199) or with pembrolizumab (I-SPY2, N = 40), or endocrine therapy (NET) without (POETIC, N = 1 ...[more]

PMID: 37935787

Similar Datasets

Project description:Currently, the occurrence and mortality rate of cervical cancer is high, particularly in low-to-middle-income countries. Therefore, the development of novel diagnostic and treatment strategies for cervical cancer is urgently required. The aim of the present study was to assess the prognostic significance of fibronectin type III domain containing 3B (FNDC3B) expression in patients with cervical cancer and to determine the underlying mechanism of FNDC3 in tumor development. Analysis of the ONCOMINE database revealed that FNDC3B was significantly upregulated in cervical cancer tissue compared with normal tissue. Additionally, FNDC3B expression data and the clinical characteristics of patients with cervical cancer were obtained from the cBioPortal database. Correlations between FNDC3B expression and overall survival were subsequently investigated. The results revealed that increased FNDC3B expression was significantly correlated with a lower overall survival in patients with cervical cancer. A co-expression network was subsequently constructed to elucidate the function of FNDC3B in cervical cancer. Co-expression genes for FNDC3B were obtained from the cBioPortal database and were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. The results demonstrated that the genes were enriched in pathways associated with migration, invasion, endoplasmic reticulum (ER) stress and the unfolded protein response (UPR). Furthermore, immunofluorescence results obtained from the Human Protein Atlas revealed that the FNDC3B protein was localized to the ER. The results revealed that upregulated FNDC3B expression may be a biomarker for poor prognosis for patients with cervical cancer. Additionally, the results revealed that FNDC3B may serve an oncogenic role in cancer development via ER stress, UPR, cell migration and invasion. However, further studies are required to determine the exact molecular mechanism of FNDC3B in the development of cervical cancer and to assess its potential as a novel therapeutic target for the treatment of this disease.

Project description:BACKGROUND:Per1, Per2, Per3, Cry1, Cry2, Bmal1, Npas2 and CLOCK genes are the eight core circadian clock genes. Low expression of these circadian clock genes plays an important role in the progression of cancers. However, its clinicopathological and prognostic value in patients with cancers remains controversial and inconclusive. We performed a meta-analysis of studies assessing the clinicopathological and prognostic significance of low expression of these genes in cancers. METHODS:Relevant studies were searched from the Cochrane Central Register of Controlled Trials, Embase, EBSCO, Ovid, PubMed, Science Direct, Wiley Online Library database, CNKI and Wan Fang database. The meta-analysis was performed by using STATA version 12 software. A random-effect model was employed to evaluate all pooled hazard ratios (HRs) and odd ratios (ORs). RESULTS:A total of 36 studies comprising 7476 cases met the inclusion criteria. Meta-analysis suggested that low expression of Per1 was associated with poor differentiation (Per1: OR=2.30, 95%CI: 1.36?3.87, P=0.002) and deeper invasion depth (Per1: OR=2.12, 95%CI: 1.62?2.77, ?<0.001); low Per2 expression was correlated with poor differentiation (Per2: OR=2.41, 95%CI: 1.53?3.79, ?<0.001), worse TNM stage (Per2:OR=3.47, 95%CI: 1.88?6.42, P<0.001) and further metastasis (Per2:OR=2.35, 95%CI: 1.35?4.11, ?=0.003). Furthermore, the results revealed that low expressions of Per1 and Per2 were also correlated with poor overall survival of cancers (Per1: HR=1.35, 95%CI: 1.06?1.72, P=0.014; Per2: HR=1.43, 95%CI: 1.10?1.85, P=0.007). Subgroup analysis indicated that low Per1 and Per2 expressions were especially associated with poor prognosis of gastrointestinal caners (Per1: HR=1.33, 95%CI: 1.14?1.55, ?<0.001, ?2=4.2%; Per2: HR=1.62, 95%CI: 1.25?2.18, P<0.001, I2=0.0%). CONCLUSIONS:Our study suggested that low Per1, Per2 and Npas2 expression played a distinct and crucial role in progression of cancers. Low expressions of Per1 and Per2 could serve as unfavorable indicators for cancers prognosis, especially for gastrointestinal cancers.

Dataset Information

Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.

Background

Methods

Results

Conclusions

Publications

Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets